Amgen’s real‑world study finds Repatha cuts heart‑attack risk by 20% versus ezetimibe
Amgen reported that a new observational study of 544,103 U.S. adults with atherosclerotic cardiovascular disease showed evolocumab (Repatha) reduced fatal or non‑fatal myocardial infarction by 20% compared with ezetimibe. The analysis, which followed patients for up to four years, found a four‑year cumulative heart‑attack risk of 5.88% for Repatha versus 7.76% for ezetimibe among the 225,048 patients with baseline LDL‑C data. The study used inverse‑probability weighting to balance baseline characteristics and was published in The American Journal of Preventive Cardiology.
Why it matters
Amgen’s chief medical officer said the findings provide clear comparative evidence that can help physicians choose between non‑statin therapies, potentially boosting Repatha’s market uptake. The 20% relative risk reduction may also support future formulary and reimbursement decisions.
Key facts
- 1The study included 544,103 adults identified in the Komodo Healthcare Map® database. prnewswire.com
- 264,421 patients initiated evolocumab and 479,682 initiated ezetimibe between 2017 and 2024. prnewswire.com
- 3Follow‑up extended through June 2026, with up to four years of observation per patient. prnewswire.com
- 4Treatment with evolocumab lowered the rate of fatal or non‑fatal myocardial infarction by 20% (hazard ratio 0.80; 95% CI 0.70‑0.91). prnewswire.com
- 5Among patients with a baseline LDL‑C measurement (N = 225,048), the four‑year cumulative heart‑attack risk was 5.88% for Repatha and 7.76% for ezetimibe. prnewswire.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.